Effect of intrauterine growth retardation on liver and long-term metabolic risk.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22531091.
- Also identified by DOI 10.1038/ijo.2012.54.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intrauterine growth retardation predisposes toward long-term morbidity from type 2 diabetes and cardiovascular disease. To explain this association, the concept of programming was introduced to indicate a process whereby a stimulus or insult at a critical period of development has lasting or lifelong consequences on key endocrine and metabolic pathways. Subtle changes in cell composition of tissues, induced by suboptimal conditions in utero, can influence postnatal physiological functions. There is increasing evidence, suggesting that liver may represent one of the candidate organs targeted by programming, undergoing structural, functional and epigenetic changes following exposure to an unfavorable intrauterine environment. The aim of this review is to provide insights into the molecular mechanisms underlying liver programming that contribute to increase the cardiometabolic risk in subjects with intrauterine growth restriction.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Fatty Liver
- Fetal Growth Retardation
- Islets of Langerhans
- Liver
- Muscle, Skeletal